Aortic regurgitation surgery
For the WikiPatient page for this topic, click here; For the main page of aortic insufficiency, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mohammed A. Sbeih, M.D.[2]; Varun Kumar, M.B.B.S., Lakshmi Gopalakrishnan, M.B.B.S; Usama Talib, BSc, MD [3]
Related Key Words and Synonyms: Aortic valve replacement.
Overview
For the WikiPatient page for this topic, click here; For the main page of aortic insufficiency, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief:Mohammed A. Sbeih, M.D.[2]; Usama Talib, BSc, MD [3] Related Key Words and Synonyms: Aortic valve replacement.
Overview
Aortic valve replacement is indicated in patients with severe aortic insufficiency who are either symptomatic or those who have a left ventricular end-diastolic diameter >55 mm or 25 mm/m2 or an left ventricular ejection fraction <55%.
The majority of patients with severe aortic regurgitation requiring surgery undergo aortic valve replacement instead of aortic valve repair which is sometimes preformed at highly specialized surgical centers which have appropriate technical expertise and experience in selecting potential patients.[1]
Advanatges of A Mechanical Valve
Mechanical valves are made of man-made (synthetic) materials, such as a metal like titanium. Mechanical heart valves do not fail often. They last from 12 to 20 years. [2][3] However, blood clots develop on them. If a blood clot forms, the patient may have a stroke. Anticoagulation with warfarin will be required which can be associated with bleeding.
Advantages of A Bioprosthetic Valve
Bioprosthetic valves are made of human or animal tissue. Biological valves do not require anticoagulation, but they tend to fail over time.[3][4]Patients with a biological valve may need to have the valve replaced in 10 to 15 years.
Selecting A Mechanical Verssus a Bioprosthetic Valve
The 2006 American College of Cardiology/American Heart Association (ACC/AHA) recommendations for the choice of aortic valve [5][6]:
- If the patient is under 65 years of age and does not have a contraindication to anticoagulation then a mechanical valve is preferred.
- If the patient is ≥65 years of age and does not have risk factors for thromboembolism, then a bioprosthetic valve is reasonable
- If the patient already has a mechanical valve in the mitral or tricuspid position and already requires anticoagulation, then a mechical valve is preferred
- If the patient has active prosthetic valve endocarditis, then the valve should be replaced
- If the patient has contraindications to anticoagulation therapy regardless his or her age, then a bioprosthetic valve is indicated
Operative Mortality
The risk of death or serious complications from isolated aortic valve replacement is typically between 1-3%, depending on the health and age of the patient, as well as the skill of the surgeon and the health care institute. The patient’s past history of heart surgery affects the mortality rate as well.
References
- ↑ Miller JG, Li M, Mazilu D, Hunt T, Horvath KA (2016). “Robot-assisted real-time magnetic resonance image-guided transcatheter aortic valve replacement”. J Thorac Cardiovasc Surg. 151 (5): 1407–12. doi:10.1016/j.jtcvs.2015.11.047. PMC 4834269. PMID 26778373.
- ↑ Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC (1991). “Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses”. N Engl J Med. 324 (9): 573–9. doi:10.1056/NEJM199102283240901. PMID 1992318.
- ↑ 3.0 3.1 Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH (2000). “Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial”. J Am Coll Cardiol. 36 (4): 1152–8. PMID 11028464.
- ↑ Hammermeister KE, Sethi GK, Henderson WG, Oprian C, Kim T, Rahimtoola S (1993). “A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease”. N Engl J Med. 328 (18): 1289–96. doi:10.1056/NEJM199305063281801. PMID 8469251.
- ↑ Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD; et al. (2008). “2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons”. Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172.
- ↑ Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G; et al. (2007). “Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology”. Eur Heart J. 28 (2): 230–68. doi:10.1093/eurheartj/ehl428. PMID 17259184.
Indications
For the WikiPatient page for this topic, click here; For the main page of AR, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Sara Zand, M.D.[2] Mohammed A. Sbeih, M.D.[3]; Rim Halaby, M.D. [4]; Usama Talib, BSc, MD [5]; Sabawoon Mirwais, M.B.B.S, M.D.[6] Synonyms and keywords: AR; Aortic Regurgitation; AVR; Aortic Valve Replacement;LVESD; Left Ventricular End Systolic Diameter;LV; Left Ventricle;LVEF;Left Ventricular Ejection Fraction;CABG;Coronart Artery Bypass Grafting;LVEDD; Left Vntricular End Diastolic Diameter;TAVI; Transcatheter Aortic Valve Replacement
Overview
Severe acute AR requires emergency surgery. The surgery should be performed as early as possible without a delay, particularly if hypotension, decreased perfusion, or pulmonary edema are present. In patients with chronic severe AR, mechanical or bioprosthetic valve may be used for valve surgery. In patients undergoing surgical replacement of the aortic sinuses and/or ascending aorta, maintaining of the native aortic valve (valve-sparing) may be possible in selected patients with favorable valve anatomy. Primary aortic valve repair is not yet generalizable, and durability is not known. AVR is recommended when there is LV dilation based on the measurement of LV in short-axis diameters. There are insufficient data on the relationship between LV volumes and outcomes of patients with AR.
Indications for Surgery for Acute Aortic Regurgitation
Timing of Emergency Surgery
Acute severe AR may cause death due to pulmonary edema, ventricular arrhythmias, electromechanical dissociation, or circulatory collapse. Individuals with bacteremia with aortic valve endocarditis should not wait for treatment with antibiotics to take effect, especially if there is hypotension, pulmonary edema, or low cardiac output given the high mortality associated with the acute AR.
Shown below is an algorithm for the treatment of acute AR.[1]
Abbreviations: AVR: Aortic valve replacement; ACE: Angiotensin converting enzyme; ARB: Angiotensin receptor blocker; CCB: Calcium channel blocker; LVEF: Left ventricle ejection fraction; TTE: Transthoracic echocardiography
| What is the cause of acute AR? | |||||||||||||||||||||||||||||
| Infective endocarditis | Aortic dissection | ||||||||||||||||||||||||||||
Does the patient have AR related heart failure symptoms? | ❑ Schedule for an emergent surgery[2] ❑ Administer beta blockers with caution (beta blockers inhibit compensatory tachycardia) | ||||||||||||||||||||||||||||
| Yes | No | ||||||||||||||||||||||||||||
❑ Schedule for early aortic valve replacement (Class I, level of evidence B)[3] | |||||||||||||||||||||||||||||
Type of Surgery
Replacement with an aortic valve homograft should be performed if feasible. The surgical approach depends upon the cause of AR. Aortic valve replacement or repair may be needed in cases of valvular structural abnormalities and aortic root repair/replacement may be needed in cases of aortic dissection.
Preoperative Medical Therapy
Patients may be temporarily managed before surgery with vasodilators such as nitroprusside and possibly inotropic agents such as dopamine or dobutamine to improve stroke volume and reduce left ventricular end-diastolic pressure.[4] Intra-aortic balloon pump is contraindicated as this would worsen aortic regurgitation by increasing afterload due to the inflation of the balloon during diastole.[5]
Mild Acute AR in the Setting of Aortic Dissection
In mild AR secondary to aortic dissection, the aortic valve can be repaired/replaced at the time of surgery for aortic dissection.
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[6]
Medical treatment to lower LV afterload may temporarily stabilize patients with acute severe AR brought on by IE or aortic dissection, but surgery should not be postponed, especially if there is hypotension, pulmonary edema, or indications of low flow. 1-4 In individuals with acute severe AR, intra-aortic balloon counterpulsation is not recommended.
Indications for Surgery for Chronic Aortic Regurgitation
Notes
- Symptoms is an important indication for AVR in patients with chronic severe AR.
- Taking a careful, detailed history regarding symptoms or reduced exercise capacity is important.
- AVR results in an improved survival rate even among symptomatic patients with a severe reduction in LVEF (<35%). [7]
- LV systolic function is an important determinant of survival and functional status after AVR.
- Optimal outcome reaches when AVR is performed before LVEF decreases below 55% or before the onset of symptoms.[8] [9]
- Other types of cardiac surgery, such as CABG, mitral valve surgery, or surgery for correction of dilation of the aortic root or ascending aorta can be performed at the time of AVR.
- LVESD in patients with chronic AR indicates both the severity of the LV volume overload and the degree of LV systolic shortening.[10]
- An elevated LVESD shows LV systolic dysfunction with a depressed LVEF. If LVEF is normal, increased LVESD indicates a significant degree of LV remodeling resulting development of symptoms and/or LV systolic dysfunction and an increased mortality rate after AVR.[11]
- Body size index is important, especially in women or small patients.
- LV volumes may be a more sensitive predictor of cardiac events than LVESD index in asymptomatic patients.
- In patients with moderate AR who are undergoing other forms of cardiac surgery, such as CABG, mitral valve surgery, or replacement of the ascending aorta, consideration of aortic valve anatomy, aortic root size and shape, regurgitant severity, other comorbidities, and patient‘s preferences and values is recommended.
- Valve-sparing procedure may be considered in patients undergoing surgical repair or replacement of the aortic root or ascending aorta.
- In asymptomatic patients with chronic AR, LVEDD is a marker of the severity of LV volume overload and associated with clinical outcomes , and progressive increases in LVEDD are associated with a further need for surgery.[12]
- TAVI for isolated chronic AR is challenging because of dilation of the aortic annulus and aortic root and lack of sufficient leaflet calcification.[13]
- Risks of TAVI for treatment of AR include transcatheter valve migration and significant paravalvular leak.
- TAVI is rarely feasible, and transcatheter approach may be performed in the selected patients with severe AR and HF, high surgical risk , with valvular calcification and appropriate annular size.
| Management of aortic regurgitation | |||||||||||||||||||||||||||||||||||||||||
| Significant enlargement of ascending aorta | Severe aortic regurgitation | ||||||||||||||||||||||||||||||||||||||||
| Surgery | Symptoms | ||||||||||||||||||||||||||||||||||||||||
| Yes | NO
| ||||||||||||||||||||||||||||||||||||||||
| Yes | |||||||||||||||||||||||||||||||||||||||||
| The above algorithm adopted from 2021 ESC Guideline[14] |
|---|
| Recommendations for surgery in severe aortic regurgitation and aortic root or tubular ascending aortic aneurysm |
| Severe aortic regurgitation (Class I, Level of Evidence B): |
|
❑ Surgery is recommended in symptomatic patients regardless of LV function |
| (Class IIb, Level of Evidence C): |
|
❑ Surgery may be considered in asymptomatic patients with LVESD >20 mm/m2 BSA (especially in patients with small body size) or resting LVEF ≤ 55%, in low risk condition |
| (Class I, Level of Evidence C) : |
|
❑ Surgery is recommended in symptomatic and asymptomatic patients with severe aortic regurgitation undergoing CABG or surgery of the ascending aorta or of another valve |
| Aortic root or tubular ascending aortic aneurysmc (irrespective of the severity of aortic regurgitation (Class I, Level of Evidence B): |
|
❑ Valve-sparing aortic root replacement is recommended in young patients with aortic root dilation |
| (Class I, Level of Evidence C): |
|
❑ Ascending aortic surgery is recommended in patients with Marfan syndrome and ascending aortic diameter ≥ 50 mm |
| (Class IIa, Level of Evidence C): |
|
❑ Ascending aortic surgery is recommended with ascending aorta size of:
Risk factors: family history of aortic dissection (or personal history of spontaneous vascular dissection), severe aortic or mitral regurgitation, desire for pregnancy, uncontrolled systemic arterial hypertension , aortic size increase >3 mm/year
❑ In the presence of primarily indication for the surgery of aortic valve, replacement of the aortic root or tubular ascending aorta should be considered
when ≥ 45 mm |
Abbreviations: BSA: Body surface area; CABG: Coronary artery bypass grafting; LV: Left ventricle; LVEF:Left ventricular ejection fraction ; LVESV:Left ventricular end-systolic diamete
| The above table adopted from 2021 ESC Guideline[14] |
|---|
Shown below is an algorithm depicting the indications for aortic valve replacement (AVR) in chronic aortic regurgitation.
| Aortic Regurgitation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Moderate Aortic Regurgitation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Severe Aortic Regurgitation ❑ VC>0.6cm ❑ Holodiastolic aortic flow reversal ❑ RVol≥60 ml ❑ RF≥ 50% ❑ ERO≥0.3cm² | Other cardiac surgery | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Symptomatic (stage D) | Asymptomatic (stage C) | AVR (Class IIa) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ❑ LVEF≤ 55% (stage C2) | ❑ Other cardiac surgerysurgery | ❑ LVEF> 55% AND ❑ LVESD > 50mm (LVESD>25mm/m² ) | ❑ Progressive decrese in LVEF to <55%-60% or increase in LVEDD to >65mm on at least 3 studies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AVR (Class I) | AVR (Class I) | AVR (Class I) | AVR (Class IIa) | Low surgical risk | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AVR (Class IIb) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbreviations: LVEF: left ventricular ejection fraction; LVEDD: left ventricular end diastolic diameter; LVESV: left ventricular end systolic diameter; VC: vena contracta; RVol: regurgitant volume; RF: regurgitant fraction; ERO: effective regurgitant orifice
| The above algorithm adopted from 2020 AHA Guideline[15] |
|---|
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[16]
Recommendations for Timing of Intervention for Chronic AR Referenced studies that support the recommendations are summarized in The Online Data Supplement
| Class I |
| 1. In symptomatic patients with severe AR (Stage D), aortic valve surgery is indicated regardless of LV systolic function(Level of Evidence: B-NR)
2. In asymptomatic patients with chronic severe AR and LV systolic dysfunction (LVEF ≤55%) (Stage C2), aortic valve surgery is indicated if no other cause for systolic dysfunction is identified(Level of Evidence: B-NR) 3. In patients with severe AR (Stage C or D) who are undergoing cardiac surgery for other indications, aortic valve surgery is indicated.(Level of Evidence: C-EO) |
| Class IIa |
| 4. In asymptomatic patients with severe AR and normal LV systolic function (LVEF >55%), aortic valve surgery is reasonable when the LV is severely enlarged (LVESD >50 mm or indexed LVESD >25 mm/m2) (Stage C2)(Level of Evidence: B-NR)
5. In patients with moderate AR (Stage B) who are undergoing cardiac or aortic surgery for other indications, aortic valve surgery is reasonable.(Level of Evidence: C-EO) |
| Class IIb |
| 6. In asymptomatic patients with severe AR and normal LV systolic function at rest (LVEF >55%; Stage C1) and low surgical risk, aortic valve surgery may be considered when there is a progressive decline in LVEF on at least 3 serial studies to the low–normal range (LVEF 55% to 60%) or a progressive increase in LV dilation into the severe range (LV end-diastolic dimension [LVEDD] >65 mm)(Level of Evidence: B-NR) |
References
- ↑ Nishimura, R. A.; Otto, C. M.; Bonow, R. O.; Carabello, B. A.; Erwin, J. P.; Guyton, R. A.; O’Gara, P. T.; Ruiz, C. E.; Skubas, N. J.; Sorajja, P.; Sundt, T. M.; Thomas, J. D. (2014). “2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines”. Circulation. doi:10.1161/CIR.0000000000000031. ISSN 0009-7322.
- ↑ “http://circ.ahajournals.org/content/121/13/e266.full”. External link in
|title=(help) - ↑ 3.0 3.1 Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). “Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America”. Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter
|month=ignored (help) - ↑ Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS (2008). “2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons”. Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Retrieved 2011-04-07. Unknown parameter
|month=ignored (help) - ↑ Rius JB, Mercè AS, del Blanco BG, Aguasca GM, Mas PT, García-Dorado García D (2011). “Resolution of shock-induced aortic regurgitation with an intraaortic balloon pump”. Circulation. 124 (4): e131. doi:10.1161/CIRCULATIONAHA.111.038653. PMID 21788594.
- ↑ Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F; et al. (2021). “2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines”. Circulation. 143 (5): e72–e227. doi:10.1161/CIR.0000000000000923. PMID 33332150 Check
|pmid=value (help). - ↑ Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ (April 1999). “Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study”. Circulation. 99 (14): 1851–7. doi:10.1161/01.cir.99.14.1851. PMID 10199882.
- ↑ Forman R, Firth BG, Barnard MS (June 1980). “Prognostic significance of preoperative left ventricular ejection fraction and valve lesion in patients with aortic valve replacement”. Am J Cardiol. 45 (6): 1120–5. doi:10.1016/0002-9149(80)90468-3. PMID 7377109.
- ↑ Bhudia SK, McCarthy PM, Kumpati GS, Helou J, Hoercher KJ, Rajeswaran J, Blackstone EH (April 2007). “Improved outcomes after aortic valve surgery for chronic aortic regurgitation with severe left ventricular dysfunction”. J Am Coll Cardiol. 49 (13): 1465–71. doi:10.1016/j.jacc.2007.01.026. PMID 17397676.
- ↑ Carabello BA, Williams H, Gash AK, Kent R, Belber D, Maurer A, Siegel J, Blasius K, Spann JF (December 1986). “Hemodynamic predictors of outcome in patients undergoing valve replacement”. Circulation. 74 (6): 1309–16. doi:10.1161/01.cir.74.6.1309. PMID 3779916.
- ↑ Bonow RO, Dodd JT, Maron BJ, O’Gara PT, White GG, McIntosh CL, Clark RE, Epstein SE (November 1988). “Long-term serial changes in left ventricular function and reversal of ventricular dilatation after valve replacement for chronic aortic regurgitation”. Circulation. 78 (5 Pt 1): 1108–20. doi:10.1161/01.cir.78.5.1108. PMID 2972417.
- ↑ Zhang Z, Yang J, Yu Y, Huang H, Ye W, Yan W, Shen H, Ii M, Shen Z (June 2015). “Preoperative ejection fraction determines early recovery of left ventricular end-diastolic dimension after aortic valve replacement for chronic severe aortic regurgitation”. J Surg Res. 196 (1): 49–55. doi:10.1016/j.jss.2015.02.069. PMID 25813142.
- ↑ Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U, Latib A, Petronio AS, Rodés-Cabau J, Taramasso M, Spaziano M, Bosmans J, Biasco L, Mylotte D, Savontaus M, Gheeraert P, Chan J, Jørgensen TH, Sievert H, Mocetti M, Lefèvre T, Maisano F, Mangieri A, Hildick-Smith D, Kornowski R, Makkar R, Bleiziffer S, Søndergaard L, De Backer O (May 2017). “Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study”. JACC Cardiovasc Interv. 10 (10): 1048–1056. doi:10.1016/j.jcin.2017.03.004. PMID 28521923.
- ↑ 14.0 14.1 Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W (February 2022). “2021 ESC/EACTS Guidelines for the management of valvular heart disease”. Eur Heart J. 43 (7): 561–632. doi:10.1093/eurheartj/ehab395. PMID 34453165 Check
|pmid=value (help). - ↑ Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C (February 2021). “2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines”. Circulation. 143 (5): e35–e71. doi:10.1161/CIR.0000000000000932. PMID 33332149 Check
|pmid=value (help). - ↑ Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F; et al. (2021). “2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines”. Circulation. 143 (5): e72–e227. doi:10.1161/CIR.0000000000000923. PMID 33332150 Check
|pmid=value (help).
Preoperative Evaluation
For the WikiPatient page for this topic, click here; For the main page of aortic insufficiency, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Varun Kumar, M.B.B.S., Lakshmi Gopalakrishnan, M.B.B.S., Mohammed A. Sbeih, M.D.[3]; Usama Talib, BSc, MD [4]
Related Key Words and Synonyms: Aortic valve replacement.
Aortic Insufficiency Preoperative Evaluation
The patient may need to have some tests before the procedure. After the diagnosis of aortic insufficiency, the general health of the patient should be assessed and the most appropriate treatment should be recommended. Some of the tests that can be done before the procedure include: [1][2][3][4][5][6][7]
- Echocardiogram (Doppler echocardiogram).
- Cardiac catheterization.
- Chest X-ray.
- Computed tomography (CT) scan.
- Electrocardiogram (ECG).
- Electrophysiology tests.
- Exercise tests.
- Holter monitor.
- Magnetic resonance imaging (MRI).
Cardiac catheterization in patients with chronic aortic insufficiency is recommended if the noninvasive diagnostic tests are inconclusive, or if the patient is at risk of coronary heart disease and the coronary anatomy should be assessed.
Before the surgery:
- The surgeon needs to know if the patient is taking any drugs, supplements, or herbs before the procedure.
- The patient may be able to store blood in the blood bank for transfusions during and after the surgery. The family members can also donate blood (autologous donation).
- For the 2-week period before surgery, the patient should be asked to stop taking drugs that make it harder for the blood to clot. These might cause increased bleeding during the surgery. Some of these drugs are aspirin, ibuprofen (Advil, Motrin), and naproxen (Aleve, Naprosyn).
- The day before the surgery, the patient should shower and shampoo well and wash the whole body below the neck with a special soap.
- The patient may also be asked to take an antibiotic to guard against infection.
- The patient should be informed which drugs he or she should still take on the day of the surgery.
- The patient should stop smoking.
On the day of the surgery:
- An intravenous (IV) line will be placed into a blood vessel in the patient’s arm or chest to give fluids and medicines.
- The patient should be asked not to drink or eat anything after midnight the night before surgery. This includes chewing gum and using breath mints. The patient can rinse mouth with water if it feels dry without swallowing.
- Make sure that the patient is taking the drugs that he or she needs to take with a small sip of water.
- Hair near the incision site may be shaved immediately before the surgery.
- The patient should be informed when to arrive to hospital on the day of the surgery.
References
- ↑ Bonow RO, Carabello B, de Leon AC, Edmunds LH, Fedderly BJ, Freed MD; et al. (1998). “ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease)”. J Heart Valve Dis. 7 (6): 672–707. PMID 9870202.
- ↑ Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). “2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines”. J Thorac Cardiovasc Surg. 148 (1): e1–e132. doi:10.1016/j.jtcvs.2014.05.014. PMID 24939033.
- ↑ Petit CJ, Gao K, Goldstein BH, Lang SM, Gillespie SE, Kim SI; et al. (2016). “Relation of Aortic Valve Morphologic Characteristics to Aortic Valve Insufficiency and Residual Stenosis in Children With Congenital Aortic Stenosis Undergoing Balloon Valvuloplasty”. Am J Cardiol. 117 (6): 972–9. doi:10.1016/j.amjcard.2015.12.034. PMID 26805657.
- ↑ Bonow RO, Carabello BA, Chatterjee K; et al. (2008). “2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons”. Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter
|month=ignored (help) - ↑ Desjardins VA, Enriquez-Sarano M, Tajik AJ, Bailey KR, Seward JB (1996). “Intensity of murmurs correlates with severity of valvular regurgitation”. Am J Med. 100 (2): 149–56. PMID 8629648.
- ↑ Grande RD, Katz WE (2011). “Acute aortic regurgitation secondary to disk embolization of a Björk-Shiley prosthetic aortic valve”. J Am Soc Echocardiogr. 24 (3): 350.e5–6. doi:10.1016/j.echo.2010.07.001. PMID 20708374.
- ↑ Miller JG, Li M, Mazilu D, Hunt T, Horvath KA (2016). “Robot-assisted real-time magnetic resonance image-guided transcatheter aortic valve replacement”. J Thorac Cardiovasc Surg. 151 (5): 1407–12. doi:10.1016/j.jtcvs.2015.11.047. PMC 4834269. PMID 26778373.
Valve Selection
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Usama Talib, BSc, MD [2]
Overview
Prior to surgery, the surgeon and patient must make a choice as to whether a mechanical or bioprosthetic valve should be inserted.
Valve Selection
Type of Valve and Discharge Anticoagulation Therapy
Shown below is an algorithm depicting the factors that influence the choice of the type of the prosthetic valve and the discharge anticoagulation therapy.[1]
Abbreviations: AVR: Aortic valve replacement; INR: International normalized ratio; TAVR Tansthoracic aortic valve replacement
Determine: ❑ Age ❑ Contraindications for anticoagulation
| |||||||||||||||||||||||||||||||||
❑ Patients ≤ 60 years old AND ❑ No contraindication for anticoagulation (Class IIa; Level of Evidence: B) | ❑ Patients 60 – 70 years old AND ❑ No contraindication for anticoagulation | ❑ Patients ≥ 70 years old (Class IIa; Level of Evidence: B) OR ❑ Patients at any age AND contraindications for anticoagulation therapy (Class I; Level of Evidence: C) | |||||||||||||||||||||||||||||||
| Bioprosthesic OR Mechanical prosthesis (Class IIa; Level of Evidence: B) | |||||||||||||||||||||||||||||||||
| Mechanical prosthesis Avoid the use of direct thrombin inhibitors or anti-Xa agents in patients with mechanical prosthesis (Class III; Level of Evidence: B) | Bioprosthesis | ||||||||||||||||||||||||||||||||
| Does the patient have risk factors for thromboembolism†? | Surgical AVR OR TAVR | ||||||||||||||||||||||||||||||||
Yes | No | Surgical AVR | |||||||||||||||||||||||||||||||
Administer for long term: ❑ Warfarin to achieve INR of 3.0 (Class I; Level of Evidence: B) AND ❑ Aspirin 75-100 mg/d (Class I; Level of Evidence: A) | Administer for long term: ❑ Warfarin to achieve INR of 2.5 (Class I; Level of Evidence: B) AND ❑ Aspirin 75-100 mg/d (Class I; Level of Evidence: A) | Administer ❑ Warfarin to achieve INR of 2.5 for 3 months (Class IIb; Level of Evidence: B) AND ❑ Aspirin 75-100 mg/d long term (Class IIa; Level of Evidence: B) | Administer:
| ||||||||||||||||||||||||||||||
Advanatges of A Mechanical Valve
Mechanical valves are made of man-made (synthetic) materials, such as a metal like titanium. Mechanical heart valves do not fail often. They last from 12 to 20 years[2][3]. However, blood clots develop on them. If a blood clot forms, the patient may have a stroke. Anticoagulation with warfarin will be required which can be associated with bleeding.
Advantages of A Bioprosthetic Valve
Bioprosthetic valves are made of human or animal tissue.Biological valves do not require anticoagulation, but they tend to fail over time [4][3]. Patients with a biological valve may need to have the valve replaced in 10 to 15 years.
Selecting A Mechanical Verssus a Bioprosthetic Valve
The 2006 American College of Cardiology/American Heart Association (ACC/AHA) recommendations for the choice of aortic valve [5][6]:
- If the patient is under 65 years of age and does not have a contraindication to anticoagulation then a mechanical valve is preferred.
- If the patient is ≥65 years of age and does not have risk factors for thromboembolism, then a bioprosthetic valve is reasonable
- If the patient already has a mechanical valve in the mitral or tricuspid position and already requires anticoagulation, then a mechical valve is preferred
- If the patient has active prosthetic valve endocarditis, then the valve should be replaced
- If the patient has contraindications to anticoagulation therapy regardless his or her age, then a bioprosthetic valve is indicated
- If the oartic root is small then a mechanical valve is indicated as there is a risk of aortic annular enlargement if a bioprosthetic valve is used
References
- ↑ Nishimura, R. A.; Otto, C. M.; Bonow, R. O.; Carabello, B. A.; Erwin, J. P.; Guyton, R. A.; O’Gara, P. T.; Ruiz, C. E.; Skubas, N. J.; Sorajja, P.; Sundt, T. M.; Thomas, J. D. (2014). “2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines”. Circulation. doi:10.1161/CIR.0000000000000031. ISSN 0009-7322.
- ↑ Bloomfield P, Wheatley DJ, Prescott RJ, Miller HC (1991). “Twelve-year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses”. N Engl J Med. 324 (9): 573–9. doi:10.1056/NEJM199102283240901. PMID 1992318.
- ↑ 3.0 3.1 Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH (2000). “Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial”. J Am Coll Cardiol. 36 (4): 1152–8. PMID 11028464.
- ↑ Hammermeister KE, Sethi GK, Henderson WG, Oprian C, Kim T, Rahimtoola S (1993). “A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease”. N Engl J Med. 328 (18): 1289–96. doi:10.1056/NEJM199305063281801. PMID 8469251.
- ↑ Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD; et al. (2008). “2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons”. Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172.
- ↑ Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G; et al. (2007). “Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology”. Eur Heart J. 28 (2): 230–68. doi:10.1093/eurheartj/ehl428. PMID 17259184.
Procedure
For the WikiPatient page for this topic, click here; For the main page of aortic insufficiency, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Varun Kumar, M.B.B.S., Lakshmi Gopalakrishnan, M.B.B.S., Mohammed A. Sbeih, M.D.[3]; Usama Talib, BSc, MD [4]
Related Key Words and Synonyms: Aortic valve replacement.
Aortic Insufficiency Surgery Procedure
If the procedure is indicated; it could be done by one of the following approaches:[1][2]
The Traditional Open Heart Surgery:
- The surgeon will make a 10-inch-long cut in the middle of the chest (sternum).
- Next, the surgeon will separate the breastbone (sternum) to be able to see the heart.
- Most people are connected to a heart-lung bypass machine or bypass pump. The heart is stopped while the patient is connected to this machine. This machine does the work of the heart while the heart is stopped.
- A small cut is made in the left side of the heart so the surgeon can repair or replace the aortic valve.
In Minimally Invasive Aortic Valve Surgery; there are several different ways to perform the procedure:
- The heart surgeon may make a 2-inch to 3-inch-long cut in the right part of the patient’s chest near the sternum. Muscles in the area will be divided so the surgeon can reach the heart. A small cut is made in the left side of the heart so the surgeon can replace the aortic valve.
- In Endoscopic surgery; the surgeon makes one to four small holes in the chest, then he or she uses special instruments and a camera to do the surgery.
- For Robotically-Assisted Valve Surgery, the surgeon makes two to four tiny cuts (about a ½ to a ¾ inch) in the chest. The surgeon uses a special computer to control robotic arms during the surgery. The surgeon sees a three-dimensional view of the heart and mitral valve on the computer. This method is very precise.
The patient may or may not need to be on a heart-lung machine for these types of surgery, but if not; the heart rate will be slowed by medicine or a mechanical device.
Once the new or repaired valve is working, the surgeon will:
- Close the heart and take you off the heart-lung machine.
- Place catheters (tubes) around the heart to drain fluids that build up.
- Close the sternum with stainless steel wires. It will take about 6 weeks for the bone to heal. The wires will stay inside the body.
The patient may have a temporary pacemaker connected to the heart until his or her natural heart rhythm returns.
The surgeon may also perform coronary artery bypass surgery at the same time, if needed.
Other aortic root diseases like marfan syndrome, bicuspid aortic valve and aortic dissection which can cause chronic aortic regurgitation should be treated with AVR and aortic root reconstruction when degree of dilatation of aorta or aortic root ≥ 50mm in diameter [3]
Ross or Ross/Konno procedure is another alternative surgical procedure where the pulmonary valve is transplanted to the aortic position, and a homograft conduit is implanted from the right ventricle to the pulmonary artery. Though this procedure shows promising results for aortic valve abnormalities in some[4][5][6], the use of this technique has been limited by high rates of pulmonary autograft failure with deterioration of right heart homografts[7]. These rates are higher in children as compared to adults. Further studies aimed at clarifying longer-term outcomes as well as preventing pulmonary homograft deteroration are needed. {{#ev:youtube|r50kKpKefP8}}
To summarize, mechanical valve replacement is the preferred surgical option at present as opposed to valve repair or biological valve replacement in view of lack of evidence of long-term durability and outcomes. However, they may be appropriate for patients in whom anticoagulation are contraindicated. Patients’ age, ability to tolerate warfarin and patients’ preference are taken into account for in deciding the type of valve (mechanical or bioprosthetic valve) to be used in valve replacement. [8]
References
- ↑ Miller JG, Li M, Mazilu D, Hunt T, Horvath KA (2016). “Robot-assisted real-time magnetic resonance image-guided transcatheter aortic valve replacement”. J Thorac Cardiovasc Surg. 151 (5): 1407–12. doi:10.1016/j.jtcvs.2015.11.047. PMC 4834269. PMID 26778373.
- ↑ Walther T, Falk V, Borger MA, Dewey T, Wimmer-Greinecker G, Schuler G; et al. (2007). “Minimally invasive transapical beating heart aortic valve implantation–proof of concept”. Eur J Cardiothorac Surg. 31 (1): 9–15. doi:10.1016/j.ejcts.2006.10.034. PMID 17097302.
- ↑ Lindsay J (1997). “Diagnosis and treatment of diseases of the aorta”. Current Problems in Cardiology. 22 (10): 485–542. PMID 9339352. Retrieved 2011-03-28. Unknown parameter
|month=ignored (help) - ↑ Ohye RG, Gomez CA, Ohye BJ, Goldberg CS, Bove EL (2001). “The Ross/Konno procedure in neonates and infants: intermediate-term survival and autograft function”. The Annals of Thoracic Surgery. 72 (3): 823–30. PMID 11565665. Retrieved 2011-04-08. Unknown parameter
|month=ignored (help) - ↑ Laudito A, Brook MM, Suleman S, Bleiweis MS, Thompson LD, Hanley FL, Reddy VM (2001). “The Ross procedure in children and young adults: a word of caution”. The Journal of Thoracic and Cardiovascular Surgery. 122 (1): 147–53. doi:10.1067/mtc.2001.113752. PMID 11436048. Retrieved 2011-04-08. Unknown parameter
|month=ignored (help) - ↑ Laforest I, Dumesnil JG, Briand M, Cartier PC, Pibarot P (2002). “Hemodynamic performance at rest and during exercise after aortic valve replacement: comparison of pulmonary autografts versus aortic homografts”. Circulation. 106 (12 Suppl 1): I57–I62. PMID 12354710. Retrieved 2011-04-08. Unknown parameter
|month=ignored (help) - ↑ David TE (2009). “Ross procedure at the crossroads”. Circulation. 119 (2): 207–9. doi:10.1161/CIRCULATIONAHA.108.827964. PMID 19153280. Retrieved 2011-04-08. Unknown parameter
|month=ignored (help) - ↑ Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS (2008). “2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons”. Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Retrieved 2011-03-29. Unknown parameter
|month=ignored (help)
Recovery
For the WikiPatient page for this topic, click here; For the main page of aortic insufficiency, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mohammed A. Sbeih, M.D.[2]; Usama Talib, BSc, MD [3]
Related Key Words and Synonyms: Aortic valve replacement.
Recovery at the Hospital
The patient may spend 4 to 7 days in the hospital after surgery (much less in Minimally invasive mitral valve surgery-3 to 5 days). Then patient will wake up in theintensive care unit (ICU) and recover there for 1 or 2 days. Two to three tubes will be in the patient’s chest to drain fluid from around the heart. They are usually removed 1 to 3 days after surgery.[1][2]
The patient may have a catheter in the bladder to drain urine, and may also have intravenous lines to get fluids. Nurses will closely watch monitors that show information about the vital signs (pulse, temperature, and breathing).
The patient will be moved to a regular hospital room from the ICU. The nurses and doctors will continue to monitor the heart and vital signs until the patient is stable enough to go home. The patient will receive pain medicine to control pain around the surgical incision site.
A nurse should help the patient to slowly resume some activity, and the patient should begin a physical therapy program to make the heart and body stronger. A temporary pacemaker may be placed in the patient’s heart if the heart rate becomes too slow after surgery.
Recovery at Home
The patient should be informed about the following:
- Taking care for his or her healing incisions.
- Recognizing signs of infection or other complications.
- Coping with after-effects of surgery.
- Followup appointments, medicines, and situations when he or she should call the doctor right away.
- When he or she can go back to daily routine, such as working, driving, and physical activity.
After-effects of heart surgery are normal. They may include muscle pain, chest pain, or swelling. Other after-effects may include loss of appetite, problems sleeping, constipation, and mood swings and depression. After-effects usually go away over time.
Less recovery time is needed for off-pump heart surgery and minimally invasive heart surgery.
Ongoing Care
Ongoing care after valve surgery may include periodic checkups with the doctor. During these visits, the patient may have blood tests, an EKG (electrocardiogram),echocardiography, or a stress test. These tests will show how the patient’s heart is working after the surgery.[2] Routine tests should be done to make sure the patient is getting the right amount of the blood-thinning medicine in case of mechanical valve placement.
The patient may be advised to change his or her lifestyle, this includes: quitting smoking, making changes to diet, being physically active, and reducing and managing stress.
References
- ↑ Disha K, Rouman M, Secknus MA, Kuntze T, Girdauskas E (2016). “Are normal-sized ascending aortas at risk of late aortic events after aortic valve replacement for bicuspid aortic valve disease?”. Interact Cardiovasc Thorac Surg. 22 (4): 465–71. doi:10.1093/icvts/ivv387. PMID 26803325.
- ↑ 2.0 2.1 Koskinas KC, Stortecky S, Franzone A, O’Sullivan CJ, Praz F, Zuk K; et al. (2016). “Post-Procedural Troponin Elevation and Clinical Outcomes Following Transcatheter Aortic Valve Implantation”. J Am Heart Assoc. 5 (2). doi:10.1161/JAHA.115.002430. PMC 4802442. PMID 26896474.
Outcomes & Prognosis
For the WikiPatient page for this topic, click here; For the main page of aortic insufficiency, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Varun Kumar, M.B.B.S., Lakshmi Gopalakrishnan, M.B.B.S., Mohammed A. Sbeih, M.D.[3]; Usama Talib, BSc, MD [4]
Related Key Words and Synonyms: Aortic valve replacement.
Overview
Most valve surgery operations are successful, but in some rare cases, an aortic valve repair may fail and another operation may be needed.
Operative Mortality
The risk of death or serious complications from isolated aortic valve replacement is typically between 1-3%, depending on the health and age of the patient, as well as the skill of the surgeon and the health care institute. The patient’s past history of heart surgery affects the mortality rate as well. Complications like myocardial Injury and acute kidney injury may negatively effect the prognosis.[1][2][3]
References
- ↑ Carrabba N, Valenti R, Migliorini A, Vergara R, Parodi G, Antoniucci D (2013). “Prognostic value of myocardial injury following transcatheter aortic valve implantation”. Am J Cardiol. 111 (10): 1475–81. doi:10.1016/j.amjcard.2013.01.301. PMID 23465097.
- ↑ Barbash IM, Dvir D, Ben-Dor I, Badr S, Okubagzi P, Torguson R; et al. (2013). “Prevalence and effect of myocardial injury after transcatheter aortic valve replacement”. Am J Cardiol. 111 (9): 1337–43. doi:10.1016/j.amjcard.2012.12.059. PMID 23415511.
- ↑ Chatani K, Abdel-Wahab M, Wübken-Kleinfeld N, Gordian K, Pötzing K, Mostafa AE; et al. (2015). “Acute kidney injury after transcatheter aortic valve implantation: Impact of contrast agents, predictive factors, and prognostic importance in 203 patients with long-term follow-up”. J Cardiol. 66 (6): 514–9. doi:10.1016/j.jjcc.2015.02.007. PMID 25801148.
Complications
For the WikiPatient page for this topic, click here; For the main page of aortic insufficiency, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Varun Kumar, M.B.B.S., Lakshmi Gopalakrishnan, M.B.B.S., Mohammed A. Sbeih, M.D.[3]; Usama Talib, BSc, MD [4]
Related Key Words and Synonyms: Aortic valve replacement.
Aortic Insufficiency Surgery Complications
Risks of any surgery Some Complications associated with any surgical procedure include:[1][2][3][4][5][6][7]
- Pulmonary embolism where blood clots in the legs travel to the lungs
- Blood loss
- Breathing problems
- Infection, including in the lungs, kidneys, bladder, chest, or heart valves
- Reactions to medicines
- Nausea and vomiting
- Abnormal or painful scar formation
- Allergic skin reaction
Possible risks from having open-heart surgery There are many risks associated with open heart surgery.[1][2]The postoperative risk factors can be related to various factors including albumin, TLC and BMI.[8] Other possible complications after an heart surgery include:[9][10][11][12]
- Heart attack or stroke
- Heart rhythm problems; such as atrial fibrillation
- Infection at the site of the incision cut, which is more likely to happen in people who are obese, have diabetes, women, or have already had this surgery
- Memory loss and loss of mental clarity, or “fuzzy thinking” or pump head
- Post-pericardiotomy syndrome, which presents as a low-grade fever and chest pain. This could last for up to 6 months
Prosthetic heart valves are associated with a variety of complications The complications associated with prosthetic heart valves include:[12][13][14][15]
- Structural deterioration, particularly with bioprosthetic valves
- Valve obstruction due to thrombosis or pannus formation
- Systemic embolization
- Bleeding
- Endocarditis and other infections
- Left ventricular systolic dysfunction, which may be preexisting (Heart failure)
- Hemolytic anemia
References
- ↑ 1.0 1.1 Carrabba N, Valenti R, Migliorini A, Vergara R, Parodi G, Antoniucci D (2013). “Prognostic value of myocardial injury following transcatheter aortic valve implantation”. Am J Cardiol. 111 (10): 1475–81. doi:10.1016/j.amjcard.2013.01.301. PMID 23465097.
- ↑ 2.0 2.1 Barbash IM, Dvir D, Ben-Dor I, Badr S, Okubagzi P, Torguson R; et al. (2013). “Prevalence and effect of myocardial injury after transcatheter aortic valve replacement”. Am J Cardiol. 111 (9): 1337–43. doi:10.1016/j.amjcard.2012.12.059. PMID 23415511.
- ↑ Chatani K, Abdel-Wahab M, Wübken-Kleinfeld N, Gordian K, Pötzing K, Mostafa AE; et al. (2015). “Acute kidney injury after transcatheter aortic valve implantation: Impact of contrast agents, predictive factors, and prognostic importance in 203 patients with long-term follow-up”. J Cardiol. 66 (6): 514–9. doi:10.1016/j.jjcc.2015.02.007. PMID 25801148.
- ↑ Escobar MA, Caty MG (2016). “Complications in neonatal surgery”. Semin Pediatr Surg. 25 (6): 347–370. doi:10.1053/j.sempedsurg.2016.10.005. PMID 27989360.
- ↑ Bechtel P, Boorse R, Rovito P, Harrison TD, Hong J (2013). “Warfarin users prone to coagulopathy in first 30 days after hospital discharge from gastric bypass”. Obes Surg. 23 (10): 1515–9. doi:10.1007/s11695-013-0972-5. PMID 23645479.
- ↑ Kumar AS, Alaparthi GK, Augustine AJ, Pazhyaottayil ZC, Ramakrishna A, Krishnakumar SK (2016). “Comparison of Flow and Volume Incentive Spirometry on Pulmonary Function and Exercise Tolerance in Open Abdominal Surgery: A Randomized Clinical Trial”. J Clin Diagn Res. 10 (1): KC01–6. doi:10.7860/JCDR/2016/16164.7064. PMC 4740618. PMID 26894090.
- ↑ Kelkar KV (2015). “Post-operative pulmonary complications after non-cardiothoracic surgery”. Indian J Anaesth. 59 (9): 599–605. doi:10.4103/0019-5049.165857. PMC 4613407. PMID 26556919.
- ↑ Gonçalves LB, Jesus NM, Gonçalves MB, Dias LC, Deiró TC (2016). “Preoperative Nutritional Status and Clinical Complications in the Postoperative Period of Cardiac Surgeries”. Braz J Cardiovasc Surg. 31 (5): 371–380. doi:10.5935/1678-9741.20160077. PMC 5144568. PMID 27982346.
- ↑ Laizo A, Delgado FE, Rocha GM (2010). “Complications that increase the time of Hospitalization at ICU of patients submitted to cardiac surgery”. Rev Bras Cir Cardiovasc. 25 (2): 166–71. PMID 20802907.
- ↑ Taniguchi FP, Souza AR, Martins AS (2007). “Cardiopulmonary bypass time as a risk factor for acute renal failure”. Rev Bras Cir Cardiovasc. 22 (2): 201–5. PMID 17992325.
- ↑ Jakob SM, Stanga Z (2010). “Perioperative metabolic changes in patients undergoing cardiac surgery”. Nutrition. 26 (4): 349–53. doi:10.1016/j.nut.2009.07.014. PMID 20053534.
- ↑ 12.0 12.1 Cheng DC, Asokumar B, Nakagawa T (1993). “Amrinone therapy for severe pulmonary hypertension and biventricular failure after complicated valvular heart surgery”. Chest. 104 (5): 1618–20. PMID 8222841.
- ↑ Sánchez E, Corrales JA, Fantidis P, Tarhini IS, Khan I, Pineda T; et al. (2016). “Thrombocytopenia after Aortic Valve Replacement with Perceval S Sutureless Bioprosthesis”. J Heart Valve Dis. 25 (1): 75–81. PMID 27989089.
- ↑ Lunardi M, Pesarini G, Zivelonghi C, Piccoli A, Geremia G, Ariotti S; et al. (2016). “Clinical outcomes of transcatheter aortic valve implantation: from learning curve to proficiency”. Open Heart. 3 (2): e000420. doi:10.1136/openhrt-2016-000420. PMC 5013502. PMID 27621826.
- ↑ Zhao Y, Cui GM, Zhou NN, Li C, Zhang Q, Sun H; et al. (2016). “Calpain-Calcineurin-Nuclear Factor Signaling and the Development of Atrial Fibrillation in Patients with Valvular Heart Disease and Diabetes”. J Diabetes Res. 2016: 4639654. doi:10.1155/2016/4639654. PMC 4830711. PMID 27123462.
Videos
Template:WH Template:WS CME Category::Cardiology
For the WikiPatient page for this topic, click here; For the main page of aortic insufficiency, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Varun Kumar, M.B.B.S., Lakshmi Gopalakrishnan, M.B.B.S., Mohammed A. Sbeih, M.D.[3]
Related Key Words and Synonyms: Aortic valve replacement.
Aortic Insufficiency Surgery Videos
Severe aortic insufficiency in patient after aortic valve replacement 1
{{#ev:googlevideo|-3829359717394053857}}
Severe aortic insufficiency in patient after aortic valve replacement 2
{{#ev:googlevideo|-1139143783733805104}}
Severe aortic insufficiency in patient after aortic valve replacement 3
{{#ev:googlevideo|-7501177211861270942}}
Severe aortic insufficiency in patient after aortic valve replacement 4
{{#ev:googlevideo|-4027195456056520519}}
Severe aortic insufficiency in patient after aortic valve replacement 5
{{#ev:googlevideo|3983126063629833286}}
Severe aortic insufficiency in patient after aortic valve replacement 6
{{#ev:googlevideo|5313961274473108141}}
Severe aortic insufficiency in patient after aortic valve replacement 7
{{#ev:googlevideo|-1049019986268408841}}
Severe aortic insufficiency in patient after aortic valve replacement 8
{{#ev:googlevideo|1577454681656420080}}
References
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
